Certain Taurine (2-Aminoethanesulfonic Acid), Methods of Production and Processes for Making the Same, and Products Containing the Same; Institution of Investigation, 8110-8112 [2019-03988]
Download as PDF
<![CDATA[
8110
Federal Register / Vol. 84, No. 44 / Wednesday, March 6, 2019 / Notices
complaint alleges violations of section
337 of the Tariff Act of 1930 (19 U.S.C.
1337) in the importation into the United
States, the sale for importation, and the
sale within the United States after
importation of certain data transmission
devices, components thereof, associated
software, and products containing the
same. The complaint names as
respondents: Apple Inc. of Cupertino,
CA; Amazon.com, Inc. of Seattle, WA;
Amazon Digital Services, LLC of Seattle,
WA; Verizon Communications Inc. of
New York, NY and Cellco Partnership
d/b/a Verizon Wireless of Basking
Ridge, NJ. The complainant requests
that the Commission issue a limited
exclusion order and cease and desist
orders.
Proposed respondents, other
interested parties, and members of the
public are invited to file comments, not
to exceed five (5) pages in length,
inclusive of attachments, on any public
interest issues raised by the complaint
or § 210.8(b) filing. Comments should
address whether issuance of the relief
specifically requested by the
complainant in this investigation would
affect the public health and welfare in
the United States, competitive
conditions in the United States
economy, the production of like or
directly competitive articles in the
United States, or United States
consumers.
In particular, the Commission is
interested in comments that:
(i) Explain how the articles
potentially subject to the requested
remedial orders are used in the United
States;
(ii) identify any public health, safety,
or welfare concerns in the United States
relating to the requested remedial
orders;
(iii) identify like or directly
competitive articles that complainant,
its licensees, or third parties make in the
United States which could replace the
subject articles if they were to be
excluded;
(iv) indicate whether complainant,
complainant’s licensees, and/or third
party suppliers have the capacity to
replace the volume of articles
potentially subject to the requested
exclusion order and/or a cease and
desist order within a commercially
reasonable time; and
(v) explain how the requested
remedial orders would impact United
States consumers.
Written submissions on the public
interest must be filed no later than by
close of business, eight calendar days
after the date of publication of this
notice in the Federal Register. There
will be further opportunities for
VerDate Sep<11>2014
18:35 Mar 05, 2019
Jkt 247001
comment on the public interest after the
issuance of any final initial
determination in this investigation. Any
written submissions on other issues
should be filed no later than by close of
business nine calendar days after the
date of publication of this notice in the
Federal Register. Complainant may file
a reply to any written submission no
later than the date on which
complainant’s reply would be due
under § 210.8(c)(2) of the Commission’s
Rules of Practice and Procedure (19 CFR
210.8(c)(2)).
Persons filing written submissions
must file the original document
electronically on or before the deadlines
stated above and submit 8 true paper
copies to the Office of the Secretary by
noon the next day pursuant to § 210.4(f)
of the Commission’s Rules of Practice
and Procedure (19 CFR 210.4(f)).
Submissions should refer to the docket
number (‘‘Docket No. 3368) in a
prominent place on the cover page and/
or the first page. (See Handbook for
Electronic Filing Procedures, Electronic
Filing Procedures 1). Persons with
questions regarding filing should
contact the Secretary (202–205–2000).
Any person desiring to submit a
document to the Commission in
confidence must request confidential
treatment. All such requests should be
directed to the Secretary to the
Commission and must include a full
statement of the reasons why the
Commission should grant such
treatment. See 19 CFR 201.6. Documents
for which confidential treatment by the
Commission is properly sought will be
treated accordingly. All information,
including confidential business
information and documents for which
confidential treatment is properly
sought, submitted to the Commission for
purposes of this Investigation may be
disclosed to and used: (i) By the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel,2 solely for cybersecurity
purposes. All nonconfidential written
submissions will be available for public
1 Handbook for Electronic Filing Procedures:
https://www.usitc.gov/documents/handbook_on_
filing_procedures.pdf.
2 All contract personnel will sign appropriate
nondisclosure agreements.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
inspection at the Office of the Secretary
and on EDIS.3
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and of §§ 201.10 and 210.8(c) of the
Commission’s Rules of Practice and
Procedure (19 CFR 201.10, 210.8(c)).
By order of the Commission.
Issued: March 1, 2019.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2019–04039 Filed 3–5–19; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1146]
Certain Taurine (2Aminoethanesulfonic Acid), Methods
of Production and Processes for
Making the Same, and Products
Containing the Same; Institution of
Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
January 30, 2019, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of Vitaworks IP, LLC of North
Brunswick, New Jersey; Vitaworks, LLC
of North Brunswick, New Jersey; and Dr.
Songzhou Hu of North Brunswick, New
Jersey. Supplemental exhibits were filed
February 19, 2019. The complaint
alleges violations of section 337 based
upon the importation into the United
States, the sale for importation, and the
sale within the United States after
importation of certain taurine (2aminoethanesulfonic acid), methods of
production and processes for making
the same, and products containing the
same by reason of infringement of
certain claims of U.S. Patent No.
9,573,890 (‘‘the ’890 patent’’); U.S.
Patent No. 9,745,258 (‘‘the ’258 patent’’);
and U.S. Patent No. 10,040,755 (‘‘the
’755 patent’’). The complaint further
alleges that an industry in the United
States exists as required by the
applicable Federal Statute.
The complainants request that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and cease and
desist orders.
ADDRESSES: The complaint, except for
any confidential information contained
SUMMARY:
3 Electronic Document Information System
(EDIS): https://edis.usitc.gov.
E:\FR\FM\06MRN1.SGM
06MRN1
Federal Register / Vol. 84, No. 44 / Wednesday, March 6, 2019 / Notices
therein, is available for inspection
during official business hours (8:45 a.m.
to 5:15 p.m.) in the Office of the
Secretary, U.S. International Trade
Commission, 500 E Street SW, Room
112, Washington, DC 20436, telephone
(202) 205–2000. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov. The public
record for this investigation may be
viewed on the Commission’s electronic
docket (EDIS) at https://edis.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Pathenia M. Proctor, The Office of
Unfair Import Investigations, U.S.
International Trade Commission,
telephone (202) 205–2560.
SUPPLEMENTARY INFORMATION:
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2018).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
February 28, 2019, ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(B) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain products
identified in paragraph (2) by reason of
infringement of one or more of claims 1
and 3–10 of the ’890 patent; claims 1–
3 of the ’258 patent; and claims 1–9 of
the ’755 patent; and whether an
industry in the United States exists as
required by subsection (a)(2) of section
337;
(2) Pursuant to section 210.10(b)(1) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.10(b)(1), the
plain language description of the
accused products or category of accused
products, which defines the scope of the
investigation, is ‘‘taurine in its raw
form, or combined with chemical
additives such as an anti-caking agent,
manufactured through processes
featuring the use of alkali isethionate or
ammonium isethionate’’;
VerDate Sep<11>2014
18:35 Mar 05, 2019
Jkt 247001
(3) Pursuant to section 210.10(b)(3) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.10(b)(3), the
presiding Administrative Law Judge
shall hold an early evidentiary hearing,
find facts, and issue an early decision,
within 100 days of institution except for
good cause shown, as to whether the
complainants have satisfied the
economic prong of the domestic
industry requirement. Notwithstanding
any Commission Rules to the contrary,
which are hereby waived, any such
decision should be issued in the form of
an initial determination (ID) under
Commission Rule 210.42(a)(3), 19 CFR
210.42(a)(3). The ID will become the
Commission’s final determination 30
days after the date of service of the ID
unless the Commission determines to
review the ID. Any such review will be
conducted in accordance with
Commission Rules 210.43, 210.44, and
210.45, 19 CFR 210.43, 210.44, and
210.45. The issuance of an early ID
finding that complainant does not
satisfy the economic prong of the
domestic industry requirement shall
stay the investigation unless the
Commission orders otherwise; any other
decision shall not stay the investigation
or delay the issuance of a final ID
covering the other issues of the
investigation;
(4) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainants are:
Vitaworks IP, LLC, 195 Black Horse
Lane, North Brunswick, NJ 08902
Vitaworks, LLC, 195 Black Horse Lane,
North Brunswick, NJ 08902
Dr. Songzhou Hu, 195 Black Horse Lane,
North Brunswick, NJ 08902
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
A to Z Nutrition, Inc., 14359 Miramar
Parkway, Suite 218, Miramar, FL
33027
Ampak Company, Inc., 1890 Palmer
Avenue, Suite 301, Larchmont, NY
10538
Armada Nutrition LLC, 4637 Port Royal
Road, Spring Hill, TN 37174
Atlantic Chemicals Trading of North
America, Inc., 2 Oliver Street, Suite
602, Boston, MA 02109
Crossroad Ingredients LLC, 271 U.S. 46
West, Suite H206, Fairfield, NJ 07004
Emote International, Inc., 1736 Wright
Avenue, La Verne, CA 91750
Epikix, Inc., 6 Imperial Aisle, Irvine, CA
92606
Fuerst Day Lawson (USA), Ltd.,
Metropolitan Wharf, 70 Wapping
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
8111
Wall, London, England E1W 3SS,
United Kingdom
Glanbia Nurtitional (NA), Inc., 2840
Loker Avenue East, Carlsbad, CA
92101
Greating Shipping Co., 2225 W.
Commonwealth Avenue, Suite 316,
Alhambra, CA 91803
Green Wave Ingredients, Inc., 14821
Northam Street, La Mirada, CA 90638
Hard Eight Nutrition, LLC, 7511
Eastgate Road, Henderson, NV 89011
Fuchi Pharmaceutical Co., Ltd. d/b/a,
Hubei Grand Life Science and
Technology Co., Ltd., 12 Wangfen
Road, Fuchi Town, Yangxin County,
Hubei Province, China 435200
Jiangyin Huachang Food Additive Co.,
Ltd., No. 152, Yingbin West Road,
Huangtu Town, JiangYin City, Jiang
Su Province, China 214445
Natural Ingredient Corp., 155 N. Lake
Avenue, 8th Floor, Suite 808,
Pasadena, CA 91101
JSW Enterprises, LLC d/b/a, Nurtavative
Ingredients, 600 Century Parkway,
Suite 200, Allen, TX 75013
N.V.E., Inc. a/k/a, N.V.E.
Pharmaceuticals, Inc., 15 Whitehall
Road, Andover, NJ 07821
Pacific Rainbow International, Inc.,
19905 Harrison Avenue, City of
Industry, CA 91789
Pharmachem Laboratories, Inc., 265
Harrison Avenue, Kearny, NJ 07032
Prinova USA, LLC, 285 E. Fullerton
Avenue, Carol Stream, IL 60188
Qianjiang Yongan Pharma. Co., Ltd., No.
2, Guangze Avenue, Economic
Development Zone, Qianjiang City,
Hubei Province, China 433132
SEM Minerals, L.P., 3806 Gardner
Expressway, Quincy, IL 62305
Signo, LLC, 2000 S. Dairy Ashford Road,
Suite 370, Houston, TX 77077
Stauber Holdings, Inc., f/k/a, Stauber
Performance Ingredients, Inc., 4120 N.
Palm Street, Fullerton, CA 92835–
1026
Shandong Xinhua Pharmaceutical USA,
Inc., d/b/a SX Pharma, 2025 Mountain
View Road, South El Monte, CA
91733
Uniprime International, LLC, 99 Corbett
Way, Eatontown, NJ 07724
Wild Flavors, Inc., 1261 Pacific Avenue,
Erlanger, KY 41018
(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street SW, Suite
401, Washington, DC 20436; and
(5) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
Responses to the complaint and the
notice of investigation must be
E:\FR\FM\06MRN1.SGM
06MRN1
8112
Federal Register / Vol. 84, No. 44 / Wednesday, March 6, 2019 / Notices
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), such
responses will be considered by the
Commission if received not later than 20
days after the date of service by the
Commission of the complaint and the
notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: February 28, 2019.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2019–03988 Filed 3–5–19; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1145]
Certain Botulinum Toxin Products,
Processes for Manufacturing or
Relating to Same and Certain Products
Containing Same; Institution of
Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
January 30, 2019, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of Medytox Inc. of South Korea;
Allergan plc of Ireland; Allergan, Inc.,
Irvine, California. Supplements to the
complaint were filed on February 12,
2019, February 13, 2019, and February
14, 2019. The complaint alleges
violations of section 337 based upon the
importation into the United States, the
sale for importation, and the sale within
the United States after importation of
SUMMARY:
VerDate Sep<11>2014
18:35 Mar 05, 2019
Jkt 247001
certain botulinum toxin products,
processes for manufacturing or relating
to same and certain products containing
same by reason of misappropriation of
trade secrets, the threat or effect of
which is to destroy or substantially
injure a domestic industry in the United
States.
The complainants request that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and cease and
desist orders.
ADDRESSES: The complaint, except for
any confidential information contained
therein, is available for inspection
during official business hours (8:45 a.m.
to 5:15 p.m.) in the Office of the
Secretary, U.S. International Trade
Commission, 500 E Street SW, Room
112, Washington, DC 20436, telephone
(202) 205–2000. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov. The public
record for this investigation may be
viewed on the Commission’s electronic
docket (EDIS) at https://edis.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Pathenia M. Proctor, The Office of
Unfair Import Investigations, U.S.
International Trade Commission,
telephone (202) 205–2560.
SUPPLEMENTARY INFORMATION:
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2018).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
February 28, 2019, ordered that—
(1) Pursuant to section 337 of the
Tariff Act of 1930, as amended, an
investigation be instituted to determine
whether there is a violation of
subsection (a)(1)(A) of section 337 in the
importation into the United States, the
sale for importation, or the sale within
the United States after importation of
certain products identified in paragraph
(2) by reason of misappropriation of
trade secrets, the threat or effect of
which is to destroy or substantially
injure a domestic industry in the United
States;
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
(2) Pursuant to section 210.10(b)(1) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.10(b)(1), the
plain language description of the
accused products or category of accused
products, which defines the scope of the
investigation, is botulinum neurotoxin
products manufactured by Daewoong
Pharmaceuticals Co., Ltd., specifically:
(1) DWP–450 (prabotulinumtoxinA),
variously marketed under the brand
names Nabota®, JeuveauTM and other
brand names; (2) products containing or
derived from DWP–450; and (3)
products containing or derived from the
BTX strain assigned the high-risk
pathogen control number 4–029–CBB–
IS–001 by the Korean Centers for
Disease Control and Prevention or the
manufacturing process used to
manufacture DWP–450;
(3) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainants are: Medytox
Inc., 626 Tehran Road, Gangnam, Seoul,
South Korea; Allergan plc, Clonshaugh
Business and Technology Park, Coolock,
Dublin, D17 E400, Irland; Allergan, Inc.,
2525 Dupont Drive, Irvine, CA 92612.
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
Daewoong Pharmaceuticals Co., Ltd.,
Bongeunsaro 114-gil 12, Gangnam,
Seoul, 06170; South Korea; Evolus, Inc.,
17901 Von Karman Avenue, Suite 150,
Irvine, CA 92614.
(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street SW, Suite
401, Washington, DC 20436; and
(4) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), such
responses will be considered by the
Commission if received not later than 20
days after the date of service by the
Commission of the complaint and the
notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
E:\FR\FM\06MRN1.SGM
06MRN1
]]>Agencies
[Federal Register Volume 84, Number 44 (Wednesday, March 6, 2019)]
[Notices]
[Pages 8110-8112]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-03988]
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1146]
Certain Taurine (2-Aminoethanesulfonic Acid), Methods of
Production and Processes for Making the Same, and Products Containing
the Same; Institution of Investigation
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that a complaint was filed with the
U.S. International Trade Commission on January 30, 2019, under section
337 of the Tariff Act of 1930, as amended, on behalf of Vitaworks IP,
LLC of North Brunswick, New Jersey; Vitaworks, LLC of North Brunswick,
New Jersey; and Dr. Songzhou Hu of North Brunswick, New Jersey.
Supplemental exhibits were filed February 19, 2019. The complaint
alleges violations of section 337 based upon the importation into the
United States, the sale for importation, and the sale within the United
States after importation of certain taurine (2-aminoethanesulfonic
acid), methods of production and processes for making the same, and
products containing the same by reason of infringement of certain
claims of U.S. Patent No. 9,573,890 (``the '890 patent''); U.S. Patent
No. 9,745,258 (``the '258 patent''); and U.S. Patent No. 10,040,755
(``the '755 patent''). The complaint further alleges that an industry
in the United States exists as required by the applicable Federal
Statute.
The complainants request that the Commission institute an
investigation and, after the investigation, issue a limited exclusion
order and cease and desist orders.
ADDRESSES: The complaint, except for any confidential information
contained
[[Page 8111]]
therein, is available for inspection during official business hours
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E Street SW, Room 112, Washington,
DC 20436, telephone (202) 205-2000. Hearing impaired individuals are
advised that information on this matter can be obtained by contacting
the Commission's TDD terminal on (202) 205-1810. Persons with mobility
impairments who will need special assistance in gaining access to the
Commission should contact the Office of the Secretary at (202) 205-
2000. General information concerning the Commission may also be
obtained by accessing its internet server at https://www.usitc.gov. The
public record for this investigation may be viewed on the Commission's
electronic docket (EDIS) at https://edis.usitc.gov.
FOR FURTHER INFORMATION CONTACT: Pathenia M. Proctor, The Office of
Unfair Import Investigations, U.S. International Trade Commission,
telephone (202) 205-2560.
SUPPLEMENTARY INFORMATION:
Authority: The authority for institution of this investigation is
contained in section 337 of the Tariff Act of 1930, as amended, 19
U.S.C. 1337, and in section 210.10 of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10 (2018).
Scope of Investigation: Having considered the complaint, the U.S.
International Trade Commission, on February 28, 2019, ordered that--
(1) Pursuant to subsection (b) of section 337 of the Tariff Act of
1930, as amended, an investigation be instituted to determine whether
there is a violation of subsection (a)(1)(B) of section 337 in the
importation into the United States, the sale for importation, or the
sale within the United States after importation of certain products
identified in paragraph (2) by reason of infringement of one or more of
claims 1 and 3-10 of the '890 patent; claims 1-3 of the '258 patent;
and claims 1-9 of the '755 patent; and whether an industry in the
United States exists as required by subsection (a)(2) of section 337;
(2) Pursuant to section 210.10(b)(1) of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10(b)(1), the plain language
description of the accused products or category of accused products,
which defines the scope of the investigation, is ``taurine in its raw
form, or combined with chemical additives such as an anti-caking agent,
manufactured through processes featuring the use of alkali isethionate
or ammonium isethionate'';
(3) Pursuant to section 210.10(b)(3) of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10(b)(3), the presiding
Administrative Law Judge shall hold an early evidentiary hearing, find
facts, and issue an early decision, within 100 days of institution
except for good cause shown, as to whether the complainants have
satisfied the economic prong of the domestic industry requirement.
Notwithstanding any Commission Rules to the contrary, which are hereby
waived, any such decision should be issued in the form of an initial
determination (ID) under Commission Rule 210.42(a)(3), 19 CFR
210.42(a)(3). The ID will become the Commission's final determination
30 days after the date of service of the ID unless the Commission
determines to review the ID. Any such review will be conducted in
accordance with Commission Rules 210.43, 210.44, and 210.45, 19 CFR
210.43, 210.44, and 210.45. The issuance of an early ID finding that
complainant does not satisfy the economic prong of the domestic
industry requirement shall stay the investigation unless the Commission
orders otherwise; any other decision shall not stay the investigation
or delay the issuance of a final ID covering the other issues of the
investigation;
(4) For the purpose of the investigation so instituted, the
following are hereby named as parties upon which this notice of
investigation shall be served:
(a) The complainants are:
Vitaworks IP, LLC, 195 Black Horse Lane, North Brunswick, NJ 08902
Vitaworks, LLC, 195 Black Horse Lane, North Brunswick, NJ 08902
Dr. Songzhou Hu, 195 Black Horse Lane, North Brunswick, NJ 08902
(b) The respondents are the following entities alleged to be in
violation of section 337, and are the parties upon which the complaint
is to be served:
A to Z Nutrition, Inc., 14359 Miramar Parkway, Suite 218, Miramar, FL
33027
Ampak Company, Inc., 1890 Palmer Avenue, Suite 301, Larchmont, NY 10538
Armada Nutrition LLC, 4637 Port Royal Road, Spring Hill, TN 37174
Atlantic Chemicals Trading of North America, Inc., 2 Oliver Street,
Suite 602, Boston, MA 02109
Crossroad Ingredients LLC, 271 U.S. 46 West, Suite H206, Fairfield, NJ
07004
Emote International, Inc., 1736 Wright Avenue, La Verne, CA 91750
Epikix, Inc., 6 Imperial Aisle, Irvine, CA 92606
Fuerst Day Lawson (USA), Ltd., Metropolitan Wharf, 70 Wapping Wall,
London, England E1W 3SS, United Kingdom
Glanbia Nurtitional (NA), Inc., 2840 Loker Avenue East, Carlsbad, CA
92101
Greating Shipping Co., 2225 W. Commonwealth Avenue, Suite 316,
Alhambra, CA 91803
Green Wave Ingredients, Inc., 14821 Northam Street, La Mirada, CA 90638
Hard Eight Nutrition, LLC, 7511 Eastgate Road, Henderson, NV 89011
Fuchi Pharmaceutical Co., Ltd. d/b/a, Hubei Grand Life Science and
Technology Co., Ltd., 12 Wangfen Road, Fuchi Town, Yangxin County,
Hubei Province, China 435200
Jiangyin Huachang Food Additive Co., Ltd., No. 152, Yingbin West Road,
Huangtu Town, JiangYin City, Jiang Su Province, China 214445
Natural Ingredient Corp., 155 N. Lake Avenue, 8th Floor, Suite 808,
Pasadena, CA 91101
JSW Enterprises, LLC d/b/a, Nurtavative Ingredients, 600 Century
Parkway, Suite 200, Allen, TX 75013
N.V.E., Inc. a/k/a, N.V.E. Pharmaceuticals, Inc., 15 Whitehall Road,
Andover, NJ 07821
Pacific Rainbow International, Inc., 19905 Harrison Avenue, City of
Industry, CA 91789
Pharmachem Laboratories, Inc., 265 Harrison Avenue, Kearny, NJ 07032
Prinova USA, LLC, 285 E. Fullerton Avenue, Carol Stream, IL 60188
Qianjiang Yongan Pharma. Co., Ltd., No. 2, Guangze Avenue, Economic
Development Zone, Qianjiang City, Hubei Province, China 433132
SEM Minerals, L.P., 3806 Gardner Expressway, Quincy, IL 62305
Signo, LLC, 2000 S. Dairy Ashford Road, Suite 370, Houston, TX 77077
Stauber Holdings, Inc., f/k/a, Stauber Performance Ingredients, Inc.,
4120 N. Palm Street, Fullerton, CA 92835-1026
Shandong Xinhua Pharmaceutical USA, Inc., d/b/a SX Pharma, 2025
Mountain View Road, South El Monte, CA 91733
Uniprime International, LLC, 99 Corbett Way, Eatontown, NJ 07724
Wild Flavors, Inc., 1261 Pacific Avenue, Erlanger, KY 41018
(c) The Office of Unfair Import Investigations, U.S. International
Trade Commission, 500 E Street SW, Suite 401, Washington, DC 20436; and
(5) For the investigation so instituted, the Chief Administrative
Law Judge, U.S. International Trade Commission, shall designate the
presiding Administrative Law Judge.
Responses to the complaint and the notice of investigation must be
[[Page 8112]]
submitted by the named respondents in accordance with section 210.13 of
the Commission's Rules of Practice and Procedure, 19 CFR 210.13.
Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be
considered by the Commission if received not later than 20 days after
the date of service by the Commission of the complaint and the notice
of investigation. Extensions of time for submitting responses to the
complaint and the notice of investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely response to each
allegation in the complaint and in this notice may be deemed to
constitute a waiver of the right to appear and contest the allegations
of the complaint and this notice, and to authorize the administrative
law judge and the Commission, without further notice to the respondent,
to find the facts to be as alleged in the complaint and this notice and
to enter an initial determination and a final determination containing
such findings, and may result in the issuance of an exclusion order or
a cease and desist order or both directed against the respondent.
By order of the Commission.
Issued: February 28, 2019.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2019-03988 Filed 3-5-19; 8:45 am]
BILLING CODE 7020-02-P
